Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional therapeutics, and LEO Pharma A/S, a global leader in medical dermatology.....
WuXi Biologics and I-Mab Biopharma jointly announce today that I-Mab has expanded strategic collaboration with WuXi Biologics and licensed proprietary WuXiBody™ Platform to develop three bispecific antibodies.